OrthoLazer Secures $7 Million in Series A Funding

OrthoLazer, the exclusive U.S. provider of MLS M8 Robotic Laser therapy for orthopedic pain, announced today the successful completion of a $7 million Series A funding round.

The investment is set to bolster the company’s expansion efforts, including the addition of innovative treatments to its orthopedic wellness centers, and will further its mission of delivering non-invasive, opioid-free pain management solutions to a growing patient base.

CEO Rod Mayer expressed excitement over the new funding, stating:

"We are thrilled to have the support of our investors who share our vision of transforming orthopedic care through our orthopedic wellness centers."

Mayer emphasized the significance of this funding as a pivotal step in accelerating OrthoLazer’s growth.

“This funding marks a significant milestone for OrthoLazer and will enable us to accelerate our growth strategy, expand our national footprint, and invest in an enhanced go-to-market model to continue providing exceptional care to our patients,” he said.

The timing of this investment is particularly important as the demand for alternative pain management solutions continues to rise. OrthoLazer’s FDA-cleared laser technology offers patients a drug-free, non-invasive approach to treating orthopedic pain and inflammation, setting the company apart as a leader in opioid-free pain relief.

Dr. Scott Sigman, Chief Medical Officer and founder of OrthoLazer, echoed Mayer’s enthusiasm. “Our mission has always been to provide effective, non-opioid pain relief options to improve patient outcomes. This investment will allow us to reach more patients and cements our commitment to advancing orthopedic care and setting new standards in the industry,” Sigman noted.

With the new funding, OrthoLazer aims to enhance both patient experience and clinical outcomes by increasing its patient acquisition efforts and raising community awareness through targeted marketing initiatives. The company’s long-term goal is to serve one million patients in a calendar year within the next few years, marking a significant leap forward in orthopedic wellness care.

"Patients today are more informed and proactive about their orthopedic care than ever before,” Mayer commented, highlighting the shift in patient behavior.

“They are seeking options that align with their personal health goals and lifestyles. We recognize this shift and expect the trend of patient empowerment to continue. That's why we're committed to providing innovative, non-invasive treatment options like our advanced laser therapy, giving patients the choices they deserve in managing their orthopedic health.”

OrthoLazer has seen consistent growth since its inception, earning recognition for its dedication to improving patient care.

This latest round of funding will enable the company to further solidify its position in the market and broaden its reach, making a more significant impact on the field of orthopedic health.

With plans to expand its offerings and enhance its market strategy, OrthoLazer is positioning itself to become the go-to orthopedic wellness center for communities across the U.S. The company remains committed to its core mission of keeping patients moving pain-free and is poised to continue transforming the landscape of orthopedic care.

The closing of this Series A round represents not only financial backing but a growing acknowledgment of the importance of alternative, opioid-free solutions for orthopedic pain management.

As OrthoLazer looks ahead, it remains focused on its commitment to patient-centric care, using innovative technology to offer safe, effective, and accessible treatment options for those suffering from orthopedic conditions.